FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against <i>Brucella</i>.

ABSTRACT:

Background

Brucellosis poses a significant public health challenge, necessitating effective vaccine development. Current vaccines have limitations such as safety concerns and inadequate mucosal immunity. This study aims to develop an FcRn-targeted mucosal Brucella vaccine by fusing the human Fc domain with Brucella's multi-epitope protein (MEV), proposing a novel approach for human brucellosis prevention.

Methods

The study developed a recombinant antigen (h-tFc-MEV) through computational analyses to validate antigenicity, structural stability, solubility, and allergenic potential. Molecular simulations confirmed FcRn binding. The vaccine was delivered orally via chitosan nanoparticles in murine models. Immunization was compared to MEV-only immunization. Post-ch

SUBMITTER: Tian T 

PROVIDER: S-EPMC12197398 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature